BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 31527169)

  • 21. Combined inhibition of Ref-1 and STAT3 leads to synergistic tumour inhibition in multiple cancers using 3D and in vivo tumour co-culture models.
    Caston RA; Shah F; Starcher CL; Wireman R; Babb O; Grimard M; McGeown J; Armstrong L; Tong Y; Pili R; Rupert J; Zimmers TA; Elmi AN; Pollok KE; Motea EA; Kelley MR; Fishel ML
    J Cell Mol Med; 2021 Jan; 25(2):784-800. PubMed ID: 33274592
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Napabucasin prevents brain injury in neuronal neonatal rat cells through suppression of apoptosis and inflammation.
    Wang J; Feng H; Li Z; Zhang X
    Microb Pathog; 2019 Mar; 128():337-341. PubMed ID: 30659911
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NAD(P)H:quinone oxidoreductase 1 reduces the mutagenicity of DNA caused by NADPH:P450 reductase-activated metabolites of benzo(a)pyrene quinones.
    Joseph P; Jaiswal AK
    Br J Cancer; 1998 Mar; 77(5):709-19. PubMed ID: 9514048
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor-selective, futile redox cycle-induced bystander effects elicited by NQO1 bioactivatable radiosensitizing drugs in triple-negative breast cancers.
    Cao L; Li LS; Spruell C; Xiao L; Chakrabarti G; Bey EA; Reinicke KE; Srougi MC; Moore Z; Dong Y; Vo P; Kabbani W; Yang CR; Wang X; Fattah F; Morales JC; Motea EA; Bornmann WG; Yordy JS; Boothman DA
    Antioxid Redox Signal; 2014 Jul; 21(2):237-50. PubMed ID: 24512128
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergistic enhancement of antitumor effect of β-Lapachone by photodynamic induction of quinone oxidoreductase (NQO1).
    Lamberti MJ; Vittar NB; da Silva Fde C; Ferreira VF; Rivarola VA
    Phytomedicine; 2013 Aug; 20(11):1007-12. PubMed ID: 23746950
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and evaluation of (±)-dunnione and its ortho-quinone analogues as substrates for NAD(P)H:quinone oxidoreductase 1 (NQO1).
    Bian J; Xu L; Deng B; Qian X; Fan J; Yang X; Liu F; Xu X; Guo X; Li X; Sun H; You Q; Zhang X
    Bioorg Med Chem Lett; 2015 Mar; 25(6):1244-8. PubMed ID: 25677663
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NAD(P)H-dependent quinone oxidoreductase 1 (NQO1) and cytochrome P450 oxidoreductase (CYP450OR) differentially regulate menadione-mediated alterations in redox status, survival and metabolism in pancreatic β-cells.
    Gray JP; Karandrea S; Burgos DZ; Jaiswal AA; Heart EA
    Toxicol Lett; 2016 Nov; 262():1-11. PubMed ID: 27558805
    [TBL] [Abstract][Full Text] [Related]  

  • 28. β-lapachone significantly increases the effect of ionizing radiation to cause mitochondrial apoptosis via JNK activation in cancer cells.
    Park MT; Song MJ; Lee H; Oh ET; Choi BH; Jeong SY; Choi EK; Park HJ
    PLoS One; 2011; 6(10):e25976. PubMed ID: 21998736
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DNA damage induced by KP372-1 hyperactivates PARP1 and enhances lethality of pancreatic cancer cells with PARP inhibition.
    Viera T; Patidar PL
    Sci Rep; 2020 Nov; 10(1):20210. PubMed ID: 33214574
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dicoumarol enhances gemcitabine-induced cytotoxicity in high NQO1-expressing cholangiocarcinoma cells.
    Buranrat B; Prawan A; Kukongviriyapan U; Kongpetch S; Kukongviriyapan V
    World J Gastroenterol; 2010 May; 16(19):2362-70. PubMed ID: 20480521
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A direct interaction between NQO1 and a chemotherapeutic dimeric naphthoquinone.
    Pidugu LS; Mbimba JC; Ahmad M; Pozharski E; Sausville EA; Emadi A; Toth EA
    BMC Struct Biol; 2016 Jan; 16():1. PubMed ID: 26822308
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors.
    Huang X; Motea EA; Moore ZR; Yao J; Dong Y; Chakrabarti G; Kilgore JA; Silvers MA; Patidar PL; Cholka A; Fattah F; Cha Y; Anderson GG; Kusko R; Peyton M; Yan J; Xie XJ; Sarode V; Williams NS; Minna JD; Beg M; Gerber DE; Bey EA; Boothman DA
    Cancer Cell; 2016 Dec; 30(6):940-952. PubMed ID: 27960087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of NADPH cytochrome P450 reductase in activation of RH1.
    Begleiter A; Leith MK; Patel D; Hasinoff BB
    Cancer Chemother Pharmacol; 2007 Oct; 60(5):713-23. PubMed ID: 17256129
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
    Bey EA; Bentle MS; Reinicke KE; Dong Y; Yang CR; Girard L; Minna JD; Bornmann WG; Gao J; Boothman DA
    Proc Natl Acad Sci U S A; 2007 Jul; 104(28):11832-7. PubMed ID: 17609380
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 2-Substituted 3,7,8-trimethylnaphtho[1,2-b]furan-4,5-diones as specific L-shaped NQO1-mediated redox modulators for the treatment of non-small cell lung cancer.
    Zhang X; Bian J; Li X; Wu X; Dong Y; You Q
    Eur J Med Chem; 2017 Sep; 138():616-629. PubMed ID: 28710963
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor.
    Hubbard JM; Grothey A
    Drugs; 2017 Jul; 77(10):1091-1103. PubMed ID: 28573435
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antioxidative enzyme NAD(P)H quinone oxidoreductase 1 (NQO1) modulates the differentiation of Th17 cells by regulating ROS levels.
    Nishida-Tamehiro K; Kimura A; Tsubata T; Takahashi S; Suzuki H
    PLoS One; 2022; 17(7):e0272090. PubMed ID: 35905076
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers.
    Bey EA; Reinicke KE; Srougi MC; Varnes M; Anderson VE; Pink JJ; Li LS; Patel M; Cao L; Moore Z; Rommel A; Boatman M; Lewis C; Euhus DM; Bornmann WG; Buchsbaum DJ; Spitz DR; Gao J; Boothman DA
    Mol Cancer Ther; 2013 Oct; 12(10):2110-20. PubMed ID: 23883585
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Specificity of human aldo-keto reductases, NAD(P)H:quinone oxidoreductase, and carbonyl reductases to redox-cycle polycyclic aromatic hydrocarbon diones and 4-hydroxyequilenin-o-quinone.
    Shultz CA; Quinn AM; Park JH; Harvey RG; Bolton JL; Maser E; Penning TM
    Chem Res Toxicol; 2011 Dec; 24(12):2153-66. PubMed ID: 21910479
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protective role of NAD(P)H:quinone oxidoreductase 1 (NQO1) in cisplatin-induced nephrotoxicity.
    Gang GT; Kim YH; Noh JR; Kim KS; Jung JY; Shong M; Hwang JH; Lee CH
    Toxicol Lett; 2013 Aug; 221(3):165-75. PubMed ID: 23831944
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.